Zacks Research Issues Optimistic Forecast for BPMC Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Zacks Research upped their Q1 2025 earnings estimates for shares of Blueprint Medicines in a research note issued to investors on Wednesday, March 5th. Zacks Research analyst A. Chakraborty now anticipates that the biotechnology company will post earnings of ($0.76) per share for the quarter, up from their previous estimate of ($0.85). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.50) EPS, FY2025 earnings at ($2.13) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.21 EPS and FY2026 earnings at $0.50 EPS.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Other equities research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Piper Sandler increased their price target on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Stephens restated an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Scotiabank assumed coverage on Blueprint Medicines in a research note on Friday. They issued a “sector outperform” rating and a $150.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.21.

Blueprint Medicines Stock Down 1.6 %

NASDAQ BPMC opened at $87.12 on Friday. The stock has a market cap of $5.57 billion, a PE ratio of -80.67 and a beta of 0.58. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The business has a 50 day moving average price of $99.38 and a two-hundred day moving average price of $94.22. Blueprint Medicines has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. This represents a 14.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 15,161 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the completion of the sale, the director now owns 152,396 shares of the company’s stock, valued at $16,691,933.88. This trade represents a 9.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,427 shares of company stock worth $4,837,801 over the last 90 days. 4.21% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of BPMC. Vanguard Group Inc. grew its stake in Blueprint Medicines by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company’s stock valued at $590,905,000 after purchasing an additional 91,450 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Blueprint Medicines by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company’s stock worth $495,331,000 after purchasing an additional 291,822 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Blueprint Medicines by 8.0% during the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company’s stock worth $373,421,000 after purchasing an additional 316,754 shares during the last quarter. State Street Corp lifted its holdings in Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after purchasing an additional 385,818 shares during the last quarter. Finally, William Blair Investment Management LLC lifted its holdings in Blueprint Medicines by 16.1% during the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company’s stock worth $169,616,000 after purchasing an additional 269,896 shares during the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.